[go: up one dir, main page]

MX2009002314A - Composiciones farmaceuticas que comprenden hgh para suministro oral. - Google Patents

Composiciones farmaceuticas que comprenden hgh para suministro oral.

Info

Publication number
MX2009002314A
MX2009002314A MX2009002314A MX2009002314A MX2009002314A MX 2009002314 A MX2009002314 A MX 2009002314A MX 2009002314 A MX2009002314 A MX 2009002314A MX 2009002314 A MX2009002314 A MX 2009002314A MX 2009002314 A MX2009002314 A MX 2009002314A
Authority
MX
Mexico
Prior art keywords
growth hormone
human growth
hgh
pharmaceutical compositions
oral delivery
Prior art date
Application number
MX2009002314A
Other languages
English (en)
Inventor
Moise Azria
Yatindra Joshi
Rosario Lobrutto
Linda Mindeholm
Ashish Bipin Patel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009002314A publication Critical patent/MX2009002314A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a formas de dosificación de la hormona de crecimiento humana, el uso de un aumentador de absorción para permitir la absorción de la hormona de crecimiento humana en la circulación sistémica en una forma biológicamente activa, en particular una administración oral, así como el uso de las formas de dosificación oral que comprenden la hormona de crecimiento humana y un aumentador de absorción para el tratamiento de las deficiencias de la hormona de crecimiento humana y desordenes saciados con la misma.
MX2009002314A 2006-08-31 2007-08-28 Composiciones farmaceuticas que comprenden hgh para suministro oral. MX2009002314A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82414006P 2006-08-31 2006-08-31
PCT/US2007/076932 WO2008027854A2 (en) 2006-08-31 2007-08-28 Pharmaceutical compositions comprising hgh for oral delivery

Publications (1)

Publication Number Publication Date
MX2009002314A true MX2009002314A (es) 2009-03-20

Family

ID=39000473

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002314A MX2009002314A (es) 2006-08-31 2007-08-28 Composiciones farmaceuticas que comprenden hgh para suministro oral.

Country Status (14)

Country Link
US (1) US8323688B2 (es)
EP (1) EP2059260B1 (es)
JP (1) JP5042312B2 (es)
KR (1) KR101524880B1 (es)
CN (2) CN103356997A (es)
AU (1) AU2007289344B2 (es)
BR (1) BRPI0716261A2 (es)
CA (1) CA2661521C (es)
ES (1) ES2426485T3 (es)
MX (1) MX2009002314A (es)
PL (1) PL2059260T3 (es)
PT (1) PT2059260E (es)
RU (1) RU2493868C2 (es)
WO (1) WO2008027854A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005995A2 (en) 2005-07-05 2007-01-11 Emisphere Technologies, Inc. Compositions for buccal delivery of human growth hormone
WO2008112836A2 (en) * 2007-03-15 2008-09-18 Novartis Ag Pharmaceutical composition comprising human growth hormon
AU2009279090A1 (en) 2008-08-06 2010-02-11 Novo Nordisk Health Care Ag Conjugated proteins with prolonged in vivo efficacy
PT2328601T (pt) 2008-08-15 2020-04-30 Ironwood Pharmaceuticals Inc Formulação sólida estável de um polipéptido agonista do recetor gc-c adequado para administração oral
US20120009225A1 (en) * 2008-09-04 2012-01-12 Ironwood Pharmaceuticals, Inc. Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral Administration
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
CN103140236B (zh) * 2009-06-08 2017-04-19 阿穆尼克斯运营公司 生长激素多肽及其制备和使用方法
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
MX2012001660A (es) 2009-08-06 2012-03-26 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para adminstracion oral.
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
CN103002918B (zh) 2010-01-22 2016-05-04 诺沃—诺迪斯克保健股份有限公司 体内功效延长的生长激素
AU2011208620B2 (en) 2010-01-22 2015-04-16 Novo Nordisk Health Care Ag Stable growth hormone compounds
ES2638589T3 (es) 2010-02-17 2017-10-23 Ironwood Pharmaceuticals, Inc. Tratamientos para trastornos intestinales
EP2595661A1 (en) 2010-07-22 2013-05-29 Novo Nordisk Health Care AG Growth hormone conjugates
MX348823B (es) 2010-08-11 2017-06-30 Forest Laboratories Holdings Ltd Formulaciones estables de linaclotida.
DK2776055T3 (en) 2011-08-17 2017-03-06 Ironwood Pharmaceuticals Inc TREATMENTS FOR GASTROINTESTINAL DISORDERS
EP2981282B1 (en) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
CN104961687B (zh) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2‑二嗪衍生物及其制剂、用途
PT3416677T (pt) 2016-02-17 2022-09-06 Genexine Inc Composição farmacêutica compreendendo hgh recombinante para o tratamento da deficiência de hormona de crescimento
JOP20190019A1 (ar) 2016-08-30 2019-02-12 Genexine Inc تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
CR20230308A (es) * 2020-12-11 2023-09-08 Civi Biopharma Inc Entrega oral de conjugados antisentido que tienen por blanco a pcsk9

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
RU2161502C2 (ru) * 1995-06-07 2001-01-10 Элкермес Контролд Терапьютикс, Инк. Композиция для пролонгированного высвобождения гормона роста человека
WO1998034632A1 (en) * 1997-02-07 1998-08-13 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1007085B1 (en) * 1997-07-04 2001-11-21 Pharmacia Aktiebolag Use of growth hormone in compositions for treating insulin resistance in the heart
CA2369591C (en) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
WO2003015822A1 (en) * 2001-08-17 2003-02-27 Novartis Ag 5-cnac as oral delivery agent for parathyroid hormone fragments
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
BR0317888A (pt) * 2002-12-31 2005-12-06 Altus Pharmaceuticals Inc Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
US7932364B2 (en) * 2003-05-09 2011-04-26 Novo Nordisk A/S Compositions and methods for the preparation of human growth hormone glycosylation mutants
WO2005004900A1 (en) * 2003-07-11 2005-01-20 Novartis Ag Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
WO2005014031A1 (en) 2003-07-23 2005-02-17 Novartis Ag Use of calcitonin in osteoarthritis
US20070037861A1 (en) * 2003-09-19 2007-02-15 Pfizer Health Ab Enhanced method of treatment of growth disorders
WO2007005995A2 (en) * 2005-07-05 2007-01-11 Emisphere Technologies, Inc. Compositions for buccal delivery of human growth hormone
SG165397A1 (en) * 2005-09-19 2010-10-28 Emisphere Tech Inc Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8- aminocaprylic acid

Also Published As

Publication number Publication date
CN103356997A (zh) 2013-10-23
CA2661521C (en) 2016-04-12
CN101557827A (zh) 2009-10-14
US8323688B2 (en) 2012-12-04
WO2008027854A3 (en) 2008-07-03
RU2493868C2 (ru) 2013-09-27
US20100247608A1 (en) 2010-09-30
CA2661521A1 (en) 2008-03-06
RU2009111391A (ru) 2010-10-10
PL2059260T3 (pl) 2014-03-31
KR101524880B1 (ko) 2015-06-01
WO2008027854A2 (en) 2008-03-06
JP5042312B2 (ja) 2012-10-03
AU2007289344A1 (en) 2008-03-06
EP2059260B1 (en) 2013-06-19
AU2007289344B2 (en) 2011-04-14
EP2059260A2 (en) 2009-05-20
JP2010502639A (ja) 2010-01-28
ES2426485T3 (es) 2013-10-23
PT2059260E (pt) 2013-09-03
KR20090045416A (ko) 2009-05-07
BRPI0716261A2 (pt) 2013-08-06

Similar Documents

Publication Publication Date Title
MX2009002314A (es) Composiciones farmaceuticas que comprenden hgh para suministro oral.
EP2248519A3 (en) Non-mucoadhesive film dosage forms
IL203747A (en) Use of a steroid sex precursor in the manufacture of a 13mg dose or less for daily dosing through the vagina to treat vaginal diseases and a vaginal pharmacological preparation containing it
IL190838A0 (en) Intranasal administration of rapid acting insulin
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
MY143795A (en) Tetrahydropyridoindole derivatives
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
MX2009003030A (es) Forma galenita para la administracion por via transmucosa de principios activos.
MX2009009132A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona.
NZ595376A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
MX2009011784A (es) Composicion para el suminitro transmucosal de polipeptidos.
DE602008006700D1 (es)
MX2011000319A (es) Uso de rifalazil para tratar trastornos colonicos.
WO2006138608A3 (en) Pharmaceutical compositions and use thereof
MX2009009134A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y nalmefeno.
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
MX2008015323A (es) Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion.
MX2010013484A (es) Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal.
WO2011028799A3 (en) Ganglioside transmucosal formulations
MX2008011321A (es) Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual.
IL179177A (en) A pharmaceutical product including acyclovir and delivery compound, dosage unit, use of acyclovir in the preparation of the pharmaceutical product, use of the pharmaceutical product in the preparation of a drug and a method for the preparation of the pharmaceutical product
PL2252263T3 (pl) Postać galenowa do podawania tryptanów poprzez błonę śluzową policzka

Legal Events

Date Code Title Description
FG Grant or registration